Farmak JSC, the leader of Ukrainian pharmaceutical industry, launched a promo website for Avouge® Biogel line, a new generation of safe products for contour plastic surgery.
The website offers reference information about Avouge® Biogel line: the cosmetic product description and indications for use.
In addition, the website shows news about Avouge® and allows getting an expert advice on specific features of the product and its use.
Nadiya Derkach, Marketing Consultant, Farmak JSC, says, “Our promo website for Avouge® Biogel line provides a tool to communicate with patients and experts, which will make it possible to communicate the information related to use and effect of Avouge® and Avouge® Plus as promptly and completely as possible. The website will also become a venue for our interactive communications with the target audience”.
Avouge® is a line of fillers for contour plastic surgery, which contain hyaluronic acid (sodium salt form) in 22 mg/ml concentration.
Hyaluronic acid forming part of Avouge® Biogels is obtained by biofermentation from Streptococcus culture using unique patented HESH-process that results in biogel with hybrid properties: elasticity of biphasic and plasticity of monophasic products.
Avouge® contains hyaluronic acid in two conditions: firstly, stabilized with butanediol diglycidyl ether and, secondly, as a linear hyaluronic acid.
The unique structure of hyaluronic acid Avouge® Biogel makes it possible to prolong the effect and achieve the desirable outcome with a smaller volume.
Crosslinking of hyaluronic acid with butanediol diglycidyl ether (BDDE), which forms part of Avouge® Biogel, facilitates prolongation of its effect.
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...